Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of VS-6063, A Focal Adhesion Kinase (FAK) Inhibitor, in Patients With KRAS Mutant Non-Small Cell Lung Cancer

NCT01951690 is registered in ClinicalTrials.gov with Verastem, Inc. as lead sponsor.

NCT NCT01951690
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01951690 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of VS-6063, A Focal Adhesion Kinase (FAK) Inhibitor, in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Lead sponsor
Verastem, Inc.
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2013
Completion date
June 30, 2016
Enrollment
55 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer, non small cell lung cancer